NRAS and melanoma: Importantly, we demonstrate that USP28 expression is deleted in ∼10% of all melanoma patients, of which half of these patient’s harbor mutations in BRAF (V600E), NF1, or NRAS, supporting a role for USP28 loss in melanoma progression.